Latest news with #non-Hispanic
San Francisco Chronicle
a day ago
- Politics
- San Francisco Chronicle
Daniel Lurie's approval rating may be sky high, but new poll reveals vulnerabilities
Despite the resounding approval San Francisco voters gave Mayor Daniel Lurie this month in the Chronicle's first poll of his tenure, the survey also suggested he has some vulnerabilities. Lurie's remarkable 73% overall favorability rating was not matched when the poll dug into specific areas of his job performance. Asked how well the mayor was doing at providing enough reasonably-priced housing, for instance, just 36% of respondents approved of his handling of the issue, versus 47% who disapproved. On providing shelter to homeless people and managing the overdose crisis, Lurie's approval was below 50%. But those ratings still represented pluralities of respondents due to the number who said they didn't know. The mayor performed strongest on his efforts to revive downtown, keep neighborhoods clean and keep residents and businesses safe from crime — all subjects that were central to his campaign and his messaging in his early months in office. Taken together, the poll results show that Lurie is enjoying a robust honeymoon a half-year into his term, even as voters harbor concerns about his ability to solve some of San Francisco's most entrenched problems. 'Mayor Lurie is delivering results on the issues San Franciscans care about,' mayoral spokesperson Charles Lutvak said in a statement to the Chronicle. 'Our administration will continue to deliver on what we've been working on relentlessly since day one: tackling the fentanyl crisis and providing safe and clean streets for everyone in our city.' Still, the mismatch between voters' sentiment about Lurie broadly and their feelings about his work on key issues suggests his rapport with the electorate could deteriorate over time if he is blamed for not making enough progress. 'I would certainly say that the challenge for the mayor and his team is to demonstrate real improvement on housing and the number of visible homeless (people),' said Jonathan Brown, president of Sextant Strategies & Research, which conducted the poll for the Chronicle. The survey respondents did not perfectly align with San Francisco's demographics. Notably, 53% of the respondents were non-Hispanic white, 16 points higher than the city's population. But Brown noted that Asian voters, who were underrepresented in the survey, gave Lurie even higher marks than the broader electorate. Corey Cook, a political scientist at Cal Poly's Solano County campus, said the fact that Lurie's approval is not as strong on the issues as it is overall is 'absolutely expected' at this point in the mayor's tenure. 'People are really anxious about these issues, but they understand the complexity of them, and it's more than just their sense of how the mayor is doing,' Cook said. 'The opportunity is that the support for the mayor can bring those numbers up. The risk is that the concern about those issues can bring the mayor's numbers down.' Over time, voters could begin to blame Lurie if they feel continued discontent around homelessness, housing and drug overdoses, Cook said. 'Or they could start to say, 'Actually, the mayor is fighting for us and doing what we want from him and there are other reasons for this, and that's who I'm mad at,'' Cook said. 'That could be anybody.' Lurie has introduced policies that seek to address the frustration San Francisco residents feel about these core issues. He released a zoning plan that would allow taller and denser buildings along certain transit corridors, seeking to pave the way for tens of thousands of new homes from the Marina to the Richmond and Sunset districts. He also passed a local law that allows him to speed up contract approvals for projects related to homelessness, mental health and drug addiction. And he increased police enforcement along corridors in the South of Market and Mission neighborhoods in response to worsening public drug scenes, while rolling out more street ambassadors to complement the work of law enforcement. Lurie, though, backed off a signature campaign promise to build 1,500 shelter beds during the first six months of his term. His administration framed the move as a decision to focus on more targeted efforts to get help to people struggling with addiction, mental illness and homelessness. Lurie's homelessness proposals have triggered some political resistance from those to the left of the moderate mayor. Progressive Supervisor Shamann Walton blasted Lurie when he pressed ahead with plans to expand a shelter in Walton's district instead of providing safe parking spots for RV dwellers that were originally planned at the site. The mayor also faced opposition from a handful of progressive supervisors when he successfully sought permission to more easily spend up to $19 million in future proceeds from a business tax that funds homeless services. 'Every dictator states that they just want additional authority once — and then they keep pressing,' Walton said of Lurie's homeless tax proposal at a recent supervisors' meeting. 'Our mayor already has a lot of power in this city … without this body allowing more.' Additionally, Lurie has drawn scrutiny over his approach to President Donald Trump, whose name he carefully avoids uttering as he tries to stay focused on local matters — and as he seeks to keep the president from focusing his vengeful politics on San Francisco. While some have questioned the mayor's Trump strategy, the Chronicle poll found that 50% of respondents thought it was the right one. Just 29% agreed with the statement that Lurie should help lead the opposition to Trump. 'Democrats are struggling with that question nationally,' said Cook, the political scientist. 'I think it's fascinating that's where San Francisco voters are right now.' Brown, the pollster, said that due to the severity of San Francisco's problems and voters' 'desire to see them remedied,' they are 'comfortable that Mayor Lurie is prioritizing local issues as opposed to national issues.'
San Francisco Chronicle
2 days ago
- Politics
- San Francisco Chronicle
How's Lurie doing as mayor? Our new poll on the state of S.F. had stunning results
Six months into Mayor Daniel Lurie's tenure, San Franciscans are far happier with his performance than they were with former Mayor London Breed's one year ago, according to a new poll commissioned by the Chronicle. The poll also revealed a turnaround in voters' attitudes about the city overall: A majority now rate the quality of life to be good or excellent, and half of respondents believe that conditions will continue to improve. The poll, which surveyed 961 registered voters between July 9 and 13, found that almost three quarters of San Franciscans approved of the job Lurie had done so far. His sky-high approval rating is almost the exact inverse of how likely voters rated Breed's performance last July: At that time, just over one quarter of respondents said they approved of the mayor's performance. The poll reflects a sampling of San Francisco residents, and was not perfectly representative of the city's demographic breakdown. Notably, even after weighting the results to better reflect the city's demographics, respondents were 53% non-Hispanic white, while the city on the whole is just 37% white. Still, the poll found no major difference between white and non-white respondents in their support of the mayor — although Asian respondents were more supportive than Black and Latino respondents. The positive results for Lurie come just six months into his term. Last July's poll on Breed, on the other hand, came six years into Breed's tenure — and months before the election. The political landscape in which the two polls were conducted has notably shifted as well. Last July, San Francisco was still struggling out of its pandemic-induced slump and grappling with a bruised national reputation. Campaigns for the mayoralty, swirling controversies around the state of the city and the presidential election were in full swing. Now, even as much of the nation's attention has shifted to President Donald Trump, his sweeping cuts to the government, his harsh immigration policies and even his feud with California Gov. Gavin Newsom, San Franciscans seem to prefer that Mayor Lurie stay out of the fray. Half of voters said the mayor should remain focused on local issues, while just 29% said Lurie should help lead the opposition. Not everyone is bullish on the mayor. Men were slightly more supportive than women, and more recent arrivals to San Francisco were more supportive than longtime residents. But the sharpest divide was political: People who identified themselves as progressives were far less likely to approve of Lurie's performance, and to be bearish on the city's future in general. Strikingly, Lurie was less popular on specific issues than he was overall. While most respondents agreed that he was keeping the city clean, keeping residents and businesses safe from crime and revitalizing downtown, he scored less favorably when it came to providing shelter for the homeless, handling the overdose crisis and addressing the cost of housing. The poll also found that San Franciscans still have mixed reviews of the Board of Supervisors: 38% of respondents said they approved of the supervisors' performance, and 46% said they disapproved. Though that's far from the ringing endorsement that Lurie enjoyed, it's much better than a year ago, when just 20% of respondents approved of the board's job, while 70% disapproved. Overall, San Franciscans are more likely now than last year to say that the city is headed in the right direction. Almost 50% of people in the new poll said they believed the quality of life in San Francisco would get better, while 23% said they believed it would get worse. Last July, 40% believed it would get better, while 32% believed it would get worse. In both years, a little over a quarter of people believed that the quality of life would stay the same. Even as a majority agree that things are looking up in the city, it's clear that a certain nostalgia for the past persists. The Chronicle asked whether respondents found the city to be more fun today than it was 10 years ago. Nearly 60% said it was more fun a decade ago. Just 13% found it more fun today.
Black America Web
11-07-2025
- Politics
- Black America Web
Black Women's Equal Pay Day Requires Equity in Policies
Source: Milko / Getty Black Women's Equal Pay Day 2025 takes place amid massive cuts and attacks on programs and policies aimed at closing the economic gap experienced by Black women and their families. Recent reports of Black women's high unemployment rates only further compound the challenges faced by Black women and their families. Each year, Black Women's Equal Pay Day marks the day in which Black women finally catch up to the earnings of white men from the year before. The day in which Black Women's Equal Pay Day is recognized varies each year, but the impact on Black women and their families remains the same. This year, Black women on average earned 66 cents as compared to non-Hispanic white men. In the South, that disparity is even more drastic. Like other commemorative days, Black Women's Equal Pay Day provides an opportunity to pause and reflect on the challenges and opportunities for addressing systemic economic disparities. As outlined by the National Black Worker Center, a combination of occupational segregation and historic discrimination rooted in slavery accounts for the extreme inequity experienced by Black women working in the South. Chandra Childers, a senior policy and economic analyst at the Economic Policy Institute, recently outlined the impact of Trump's cuts and public sector disinvestment on Black women. 'The public sector includes workers in federal, state, and local government that we all rely on to educate children across the region, care for sick and elderly family members, ensure food and water are safe to consume, provide public transportation and sanitation services, and ensure access to a wide range of other public services,' wrote Childers. 'The decline in public-sector job quality across the South disproportionately harms Black workers, especially Black women, their families, and communities.' It's estimated that over 40 years, Black women lose out on $1 million in earnings. Even if Black women were suddenly paid the same as their white male counterparts, it would take an estimated 200 years before Black women working full-time achieved true economic parity. Achieving equal pay for Black women demands policies and the political will to ensure enforcement over the long haul. Policy agendas like the Black Women Best Framework and the recently introduced Black Reproductive Justice Policy Agenda by In Our Own Voice provide a blueprint for improving economic and social conditions for Black women. 'Despite historic unemployment rates for Black workers being double the rate of White workers, Black women's persistent labor force participation is not merely admirable — it is a reflection of generational resilience in the face of enduring labor market injustice,' wrote Miriam Van Dyke, research manager at Kindred Futures. 'We must uplift Black women and allow them to thrive as they have continued to raise and sacrifice for the Black community and larger society.' SEE ALSO: Unemployment Rate Remained Stubbornly High For Black Women In June BLD PWR, SisterSong, GBEF Host Houston Juneteenth Event SEE ALSO Black Women's Equal Pay Day Requires Equity in Policies was originally published on
Yahoo
08-07-2025
- Health
- Yahoo
Hope on the Horizon: Cutting-Edge Therapies Redefine Outcomes in Glioblastoma Multiforme Treatment making the global market to nearly double by 2033 and grow with a CAGR of 8.5%
The glioblastoma multiforme treatment market is expected to grow significantly and reach USD 6.1 billion by 2033, driven by a rising prevalence, growing R&D investment in novel therapies and favorable reimbursement support. New vaccine-based approaches are emerging as key areas of focus. Chicago, July 08, 2025 (GLOBE NEWSWIRE) -- The global glioblastoma multiforme treatment market was valeud at US$ 3.0 billion in 2024 and is expected to reach USD 6.1 billion by 2033, growing at a CAGR of 8.5% from 2025-2033. This expansion is fueled by rising disease prevalence, advances in diagnostics, growing R&D investments, and emerging targeted therapies. However, challenges such as the blood-brain barrier, therapeutic resistance, and limited long-term efficacy constrain progress and deter commercial investment. Despite these hurdles, innovation across therapeutic modalities and supportive technologies is gradually reshaping the treatment landscape. Explore Key Data Points and Forecast Tables in the Free Sample Copy: Glioblastoma Multiforme is the most common type of cancerous brain tumor. It poses significant treatment challenges due to its rapid proliferation, invasive growth, and resistance to conventional therapies. It is characterized by necrosis, microvascular proliferation, and marked cellular atypia. As per the American Association of Neurological Surgeons in 2024, glioblastoma multiforme accounted for 47.7% of malignant brain and CNS tumors, with an incidence of 3.2 per 100,000 and a prevalence of 9.2 per 100,000 in the U.S. According to the National Brain Tumor Society, the median survival is 14.6 months, with only 17% of patients alive after two years and a five-year survival rate of just 6.8%. It is more common in males, peaks between ages 75 – 84, and shows racial disparities, with highest incidence among non-Hispanic white populations. Treatment typically involves surgical resection followed by chemoradiation with temozolomide, which remains the standard of care (SoC). However, recurrence occurs in over 90% of patients within two years. For recurrent cases, bevacizumab (Avastin) and combinations like lomustine-bevacizumab offer modest benefits. Device-based therapies, such as Tumor Treating Fields (TTFields), continue gaining traction with FDA-approved systems like Optune Gio. Novel therapies, including selinexor (NCT04216329) and immune checkpoint inhibitors like nivolumab (NCT04606316), are currently in clinical trials, signaling progress towards durable Forecast (2033) USD 6.1 billion CAGR 8.5% Top Driver (s) Growing Prevalence of glioblastoma multiformeFavorable reimbursement policies Demand for effective treatment Top Trend Adoption of TTFields devices Top Restraint Consistently low survival rates in glioblastoma multiforme Opportunity Unlocked: Glioblastoma Vaccines as the Next Frontier in Immunotherapy Glioblastoma multiforme is hard to treat with conventional therapies. However, breakthroughs in vaccine-based immunotherapy are beginning to reshape the therapeutic landscape, offering new hope for the patients. Research efforts are accelerating around multiple vaccine platforms, including peptide-based, dendritic cell (DC), and mRNA vaccines, highlighting a new era of personalized and immune-driven treatment strategies. Peptide vaccines, such as SurVaxM developed by MimiVax and currently in Phase II clinical trials, are designed to target tumor-specific neoantigens, activating the immune system to selectively attack malignant cells. These personalized vaccines have shown potential in extending progression-free survival and enhancing immune engagement. Similarly, DC vaccines are gaining traction, despite logistical challenges in integration with standard therapies. Notable candidates such as DCVax-L, in Phase III trials for newly diagnosed and recurrent glioblastoma multiforme, and DOC1021, currently in Phase II trials by Diakonos, have demonstrated improved two-year survival rates when administered sequentially after temozolomide (TMZ) chemotherapy, rather than concurrently. Meanwhile, mRNA-based vaccines are emerging as a powerful immunotherapeutic modality, leveraging their rapid development cycle and capacity to induce strong, targeted immune responses against glioblastoma multiforme cells. Their adaptability and precision position them as a key component in next-generation oncology protocols. While the momentum is promising, ongoing research aims to refine delivery systems, address tumor-induced immunosuppression, and explore synergistic combinations with checkpoint inhibitors and standard-of-care therapies. Collectively, the expanding pipeline of glioblastoma vaccines signifies a paradigm shift toward more personalized, immune-based interventions, marking a transformative step forward in the quest for more durable and effective glioblastoma multiforme treatment. Regional Dynamics Shaping the Glioblastoma Multiforme Treatment Landscape The global glioblastoma multiforme treatment market is evolving rapidly, with regional dynamics playing a pivotal role in shaping its growth. North America leads the market, driven by advanced healthcare infrastructure, streamlined regulatory frameworks, and strong R&D investment. The U.S. Consolidated Appropriations Act of 2024 allocated $10 million to establish the Glioblastoma Research Program (GBMRP) under CDMRP, while Canada's Lundin Cancer Fund committed $4 million in 2025 to launch a national glioblastoma multiforme initiative, reinforcing the region's leadership in clinical innovation. Europe follows closely, propelled by coordinated national research strategies and strong public funding. Germany's UNITE Glioblastoma project, supported by the German Research Foundation's Collaborative Research Centers, exemplifies the region's growing commitment to tackling glioblastoma multiforme through advanced research and cross-border collaboration. The Asia-Pacific region is witnessing rapid progress, with governments, academia, and private stakeholders stepping up investment. Japan's conditional approval of DELYTACT (G47∆) the world's first oncolytic virus therapy for malignant gliomas, highlights the region's increasing role in therapeutic innovation. Meanwhile, the Middle East and Africa are in the early stages of glioblastoma multiforme research development. Though challenged by limited infrastructure and funding, emerging efforts from academic centers and private healthcare providers are laying the groundwork for future growth and capacity-building. As glioblastoma multiforme remains one of the most aggressive brain cancers, regional efforts will continue to shape the global response, advancing innovation, access, and treatment outcomes. Recent Advancements and Key Players in the Glioblastoma Therapeutics Market Several prominent players, including Novocure, Roche, Merck & Co., Novartis, Daiichi Sankyo, Allergan, Laminar Pharmaceuticals, Vigeo Therapeutics, Eli Lilly, Incyte Corporation, Kazia Therapeutics, and TVAX Biomedical, are advancing innovation in the glioblastoma treatment landscape. These companies are focused on developing novel therapeutics, targeted drug delivery systems, and strategic collaborations to tackle one of the most aggressive forms of brain cancer. In March 2025, Laminar Pharmaceuticals announced promising results from its ongoing Phase 2b/3 clinical trial (NCT04250922) of LAM561 in newly diagnosed glioblastoma (ndGBM). The randomized, double-blind, placebo-controlled study evaluates LAM561 in combination with standard chemoradiotherapy (radiotherapy and temozolomide). Early data revealed a positive trend in progression-free survival (PFS), particularly in patients with MGMT-methylated tumors. The trial is partially supported by the EU H2020 ClinGlio initiative, reinforcing the importance of public-private partnerships in advancing brain cancer research. Similarly, on June 2, 2025, Sapience Therapeutics presented updated clinical and biomarker data from its ongoing Phase 2 trial of Lucicebtide (formerly ST101) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Lucicebtide, a first-in-class C/EBPβ antagonist, demonstrated encouraging results in glioblastoma patients, further validating its mechanism of action and potential as a novel targeted therapy. Further driving progress, on April 1, 2025, Spanios and GlioGuard announced a strategic partnership to accelerate glioblastoma drug discovery and development. This collaboration aims to deliver more effective and personalized treatment options for glioblastoma multiforme, addressing the urgent need for breakthroughs in one of the most treatment-resistant forms of cancer. These advancements highlight the growing momentum in glioblastoma therapeutics. With continued innovation, clinical progress, and collaborative efforts, the industry is poised to improve patient outcomes and reshape the future of brain cancer treatment. Book a 1:1 Presentation to Discuss Key Trends and Strategic Takeaways: Future Outlook: Evolving the Glioblastoma Multiforme Treatment Landscape The glioblastoma multiforme treatment market is under transformation. By 2030, a combination of drug innovation, device advancement, and integrated care models is expected to redefine survival outcomes for this aggressive brain cancer. Oral therapies currently lead the market, driven by ease of use and improved patient adherence. Injectables follow, offering systemic options like chemotherapies and targeted biologics. Implants, such as localized wafers, remain a niche but vital component post-surgery. Therapies, especially multi-modal regimens, dominate the market and are expanding rapidly, as combination approaches become the clinical standard. The next wave will be led by immunotherapies and immune checkpoint inhibitors, poised to break the disease immune resistance. These emerging treatments will increasingly complement traditional modalities, aiming for longer progression-free and overall survival. Wearable devices, particularly Novocure's Optune Gio, represent a paradigm shift. Future versions will be lighter, more personalized, and AI-integrated, enabling real-time therapy adjustments and remote monitoring, bringing glioblastoma multiforme care closer to the patient. Key Competitors Novocure Roche Merck & Co. Novartis Daiichi Sankyo Allegran Laminar pharmaceuticals Vigeo therapeutics Eli lily Incyte corporation Kazia Therapuetics TVAX Biomedicals Segmentation: Glioblastoma Multiforme Treatment Market By Treatment Type Surgery (Gliadel wafer) Therapies Chemotherapy Temzolomide Lomustine Radiation Therapy Targeted Therapy (Bevacizumab) Others (Delytact) Tumor Treating Fields (TTF) (Optune Gio) By Dosage Form Oral Injectables Implant and TFF Field Device By End Users Hospitals & Clinics (specialty clinics) Cancer Treatment Centers Academic and Research Organizations By Region North America South America Europe Asia Pacific Middle East and Africa Still Have Questions? Contact Us for Clarification or a Custom Data Request: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
05-07-2025
- Business
- Miami Herald
Corona beer owner raises red flag about alarming consumer trend
Constellation Brands (STZ) , which owns top beer brands Corona and Modelo, has been struggling to attract customers over the past few months, and its CEO is calling out the source of the problem. In Constellation Brands' first-quarter earnings report for 2025, it revealed that its net sales in beer declined by 2% year-over-year, while net sales in wine and spirits decreased by a whopping 28%. Don't miss the move: Subscribe to TheStreet's free daily newsletter The sharp decline in sales contributed to the company generating only $714 million in operating income, which is 24% lower than what it earned during the same time period last year. Related: Coca-Cola suffers an alarming loss from major boycott In the report, Constellation Brands said that "the current socioeconomic environment" contributed to weak consumer demand. During an earnings call on July 1, Constellation Brands CEO Bill Newlands said the company saw a "significant amount of consumer concern" during the quarter, especially among Hispanic and non-Hispanic consumers, which has prompted a sharp change in their spending habits. "Both Hispanic and non-Hispanic consumers are concerned about inflation and about cost structure," said Newlands. "But I also would point out that the percentage of alcohol in the basket has remained constant, even though the basket has gotten smaller relative to what consumers are doing with consumer goods." This concern comes at a time when inflation remains high, and President Donald Trump's tariff policy has led to uncertainty about the economy, raising worries about a possible recession. According to a recent survey from market research company Numerator, 64% of consumers are worried that tariffs will raise prices on everyday goods. Related: Corona beer owner flags a startling shift in consumer behavior Newlands emphasized that Hispanic customers reflect about half of Constellation Brands' business, and they still remain "very interested" in beer. However, they are, like many other consumer groups, scaling back social gatherings to save money. "So when [we] look at the fact that consumers are not going out to eat as much as they had; they're having less social occasions at home, [but] it doesn't change their interest in consumption of beer," said Newlands. "It simply has been that those occasions have been decreased." Constellation Brands recently conducted a survey of both Hispanic and non-Hispanic consumers and found that 70% of consumers are concerned about their personal finances. In response to these worries, consumers said that they have scaled back social gatherings with friends and family in public spaces and at homes over the past three months. They are also shopping less at convenience stores or gas stations, two of the top places to purchase alcoholic beverages. To help combat this alarming consumer trend, Constellation Brands is making a few tweaks to its pricing. "I would point out where we're spending a lot of time is in price pack an area where as the consumer may be more concerned about inflationary trends, it would be important to have the right pack set at the right price points, so that no matter what the consumer has available to them to spend, we have a product available," said Newlands. The weak consumer demand also comes during a time when many Americans are changing their tune about alcohol consumption. More Retail: Costco quietly plans to offer a convenient service for customersT-Mobile pulls the plug on generous offer, angering customersAT&T makes generous offer to older customers A survey from Gallup last year found that 45% of Americans believe drinking one or two alcoholic beverages a day is harmful to one's health. This is a six-percentage-point increase, compared to results from last year, and a 17-point increase compared with responses in 2018. Amid this change in attitude, beer, wine, and spirit sales in the U.S. declined in 2024. In addition, then-U.S. Surgeon General Dr. Vivek Murthy released an advisory in January that highlights a direct link between alcohol consumption and increased cancer risk. The advisory may make it extra challenging for the alcohol industry to experience a quick recovery in sales. Related: Chick-fil-A angers customers with major change in stores The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
